Increased expression levels of p53 correlate with good response to cisplatin-based chemotherapy in non-small cell lung cancer

Oncology Reports

Volumn 7, Issue 6, 2000, Pages 1225-1228

  Oshita, Fumihiro ^a   Nishio, Kazuto ^b   Kameda, Yoichi ^a   Mitsuda, Aki ^a   Ikehara, Mizuki ^a   Tanaka, Gaku ^a   Yamada, Kouzo ^a   Nomura, Ikuo ^a   Noda, Kazumasa ^a   Arai, Hiromasa ^a   Ito, Hiroyuki ^a   Nakayama, Haruhiko ^a  

^a KANAGAWA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

cdk; Cisplatin; Immunostaining

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; CISPLATIN; DRUG DERIVATIVE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; PROTEIN P53; VINDESINE;

AGED; ARTICLE; BIOSYNTHESIS; DISEASE FREE SURVIVAL; FEMALE; GENE EXPRESSION; GENETICS; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALE; METABOLISM; MIDDLE AGED; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION; HUMANS; IFOSFAMIDE; LUNG NEOPLASMS; MALE; MIDDLE AGED; MITOMYCIN; NEOPLASM RECURRENCE, LOCAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53; VINDESINE;

EID: 0034320227     PISSN: 1021335X     EISSN: None     Source Type: Journal    
DOI: 10.3892/or.7.6.1225     Document Type: Article

References (19)

1. Shinkai T, Eguchi K, Sasaki Y, et al: A prognostic-factor risk index in advanced non-small cell lung cancer treated with cisplatin-containing combination chemotherapy. Cancer Chemother Pharmacol 30: 1-6, 1992.
2. Oshita F, Yamamoto N, Fukuda M, et al: Correlation of therapeutic outcome in non-small cell lung cancer and DNA damage assayed by polymerase chain reaction in leukocytes damaged in vitro. Cancer Res 55: 2334-2337, 1995.
3. Oshita F and Saijo N: Use of the polymerase chain reaction to measure variations in gene-specific repair of cisplatin-induced DNA damage between cisplatin-sensitive and -resistant lung cancer cell lines, and in mononuclear cells of lung cancer patients. Cell Pharmacol 2: 205-209, 1995.
4. McGrill G and Fisher DE: Apoptosis in tumorigenesis and cancer therapy. Frontiers Biosci 2: 353-379, 1997.
5. Reed JC, Miyashita T, Takayama S, et al. BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 60: 23-32, 1996.
6. Rudin CM and Thompson CB: Apoptosis and disease: regulation and clinical relevance of programmed cell death. Annu Rev Med 48: 267-281, 1997.
7. Quinlan DC, Davidson AG, Summers CL, et al: Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52: 4828-4831, 1992.
8. Lee JS, Yoon A, Kalapurakal SK, et al: Expression of p53 oncoprotein in non-small cell lung cancer: a favorable prognostic factor. J Clin Oncol 13: 1893-1903, 1995.
9. McLaren R, Kuzu I, Dunnill M, et al: The relationship of p53 immunostaining to survival in carcinoma of the lung. Br J Cancer 66: 735-738,1992.
10. World Health Organization: WHO Hand Book for Reporting Results of Cancer Treatment. WHO Offset Publication No. 48., World Health Organization, Geneva, 1979.
11. Ko LJ and Prives C: p53: puzzle and paradigm. Genes Dev 10: 1054-1072, 1996.
12. Levine AJ: p53, the cellular gatekeeper for growth and division. Cell 88: 323-331, 1997.
13. Anthoney DA, Mcllwrath AJ, Gallagher WM, et al: Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res 56: 1374-1381, 1996.
14. Perego P, Giarola M, Righetti SC, et al: Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562, 1996.
15. Gallagher WM, Cairney M, Schott B, et al: Identification of p53 genetic suppressor elements which confer resistance to cisplatin. Oncogene 14: 185-193, 1997.
16. Fujiwara T, Grimm EA, Mukhopadhyay T, et al: Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54: 2287-2291, 1994.
17. Zamble DB, Jacks T and Lippard SJ: p53-dependent and -independent responses to cisplatin in mouse testicular teratocarcinoma cells. Proc Natl Acad Sci USA 95: 6163-6168, 1998.
18. Fans S, Chang JK, Smith ML, et al: Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. Oncogene 14: 2127-2136, 1997.
19. O'Connor PM, Jackman J, Bae I, et al: Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300, 1997.